The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 351:2340-2342 November 25, 2004 Number 22
NextNext

Peginterferon plus Ribavirin for Hepatitis C in HIV-Infected Patients

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Torriani, F. J.
-Related Article
by Chung, R. T.
-PubMed Citation
To the Editor: Torriani and colleagues' report of the AIDS Pegasys Ribavirin International Coinfection Trial (APRICOT) and Chung and colleagues' report of the Adult AIDS Clinical Trials Group (ACTG) A5071 trial of treatment for hepatitis C virus (HCV) infection in patients coinfected with the human immunodeficiency virus (HIV) (July 29 issue)1,2 may provide data to refute the recommendation that pegylated interferon and ribavirin be prescribed when the CD4+ cell count is above 350 per cubic millimeter and deferred when it is less than 200 per cubic millimeter.3 APRICOT enrolled 51 patients with a CD4+ cell count of less than 200 . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.